Posaconazole treatment in hematology patients: A pilot study of therapeutic drug monitoring

Therapeutic Drug Monitoring

Volumn 34, Issue 3, 2012, Pages 320-325

  Crombag, Marie Rose B S ^a,b   Huisman, Cynthia ^a   Kemper, Elles M ^a   Brüggemann, Roger J M ^a,c   Bijleveld, Yuma A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dosage optimization; Invasive fungal infection (IFI); Prophylaxis; Proton pump inhibitor (PPI); Therapeutic drug monitoring

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; CASPOFUNGIN; CORTICOSTEROID; CREATININE; CYCLOSPORIN; DOXEPIN; EFAVIRENZ; ESOMEPRAZOLE; GAMMA GLUTAMYLTRANSFERASE; HISTAMINE H2 RECEPTOR ANTAGONIST; METOCLOPRAMIDE; PHENYTOIN; POSACONAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN; RIFAMPICIN; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ANALYTIC METHOD; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COMORBIDITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; ELECTRONIC MEDICAL RECORD; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; LIQUID CHROMATOGRAPHY; LUNG ASPERGILLOSIS; MALE; MEASUREMENT; MYCOSIS; PATIENT MONITORING; PILOT STUDY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SALVAGE THERAPY; TANDEM MASS SPECTROMETRY; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS;

ADULT; ANTIFUNGAL AGENTS; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; MYCOSES; PILOT PROJECTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84861229084     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31824d135c     Document Type: Article

References (21)

1. Smith WJ, Drew RH, Perfect JR. Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update. Expert Rev Anti Infect Ther. 2009;7:165-181.
2. US Food and Drug Administration. Official Product Information Noxafil (Posaconazole). Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2009/022003s007lbl.pdf. Accessed July 1, 2010.
3. European Medicines Agency. Summary of Product Characteristics: Noxafil (Posaconazole). Available at: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000610/WC500037784.pdf. Accessed July 1, 2010.
4. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348-359. (Pubitemid 46148777)
5. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356: 335-347. (Pubitemid 46148776)
6. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44:2-12. (Pubitemid 44968977)
7. Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther. 2010;88:115-119.
8. Lebeaux D, Lanternier F, Elie C, et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother. 2009;53:5224-5229.
9. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53:24-34.
10. Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48:1441-1458.
11. Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy. 2007;27:1627-1636. (Pubitemid 350234311)
12. Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53:958-966.
13. Worth LJ, Blyth CC, Booth DL, et al. Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. Intern Med J. 2008;38:521-537. (Pubitemid 351904423)
14. Neubauer WC, Engelhardt M, Konig A, et al. Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method. Antimicrob Agents Chemother. 2010;54:4029-4032.
15. De Pauw B,Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46: 1813-1821.
16. Bruggemann RJ, Touw DJ, Aarnoutse RE, et al. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother. 2009; 53:303-305.
17. Sansone-Parsons A, Krishna G, Martinho M, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy. 2007;27:825-834. (Pubitemid 46849426)
18. Cornely OA, Ullmann AJ. Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther. 2011;89:351-352.
19. Moton A, Krishna G, Wang Z. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. J Clin Pharm Ther. 2009;34:301-311.
20. Ezzet F, Wexler D, Courtney R, et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet. 2005;44: 211-220. (Pubitemid 40188942)
21. Alffenaar JW, van AS, van der Werf TS, et al. Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis. 2009;48:839.